MUC1 and neoplasm: Additionally, studies have shown that engineered CAR-T cells targeting mucin 1 (MUC1) and CD276 can induce the release of high levels of cytokines, achieving better persistence and durability to regulate a stronger anti-tumor response in a subcutaneous xenograft mouse model of EC (39, 40); this indicates that CAR-T cell therapy merits testing in EC clinical trials in the future.